RxDoctor Payments Data

Edward Pankey

Internal Medicine · Akron, OHNPI 1285020537

Payments from drug & device makers

$886in general payments, 2019–2025

Across 16 payments — averaging $55.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$356
  • Nevro Corp.$267
  • Medtronic$123
  • Flowonix Medical Incorporated$43
  • Abbott$38
  • Dynavax Technologies Corporation$17
  • plus $41 from 3 others

What the payments were for

  • Travel & lodging$61%
  • Food & beverage$88099%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$886 in reported general payments places this provider in the 70th percentile of 4,428 internal medicine providers in Ohio.

See all internal medicine providers in Ohio

Medicare billing

Part B allowed, 2024
$28,355
Medicare patients
98
Services billed
344

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TrulicityDulaglutide125$139,131
EliquisApixaban91$82,700
OzempicSemaglutide64$73,635
JardianceEmpagliflozin42$48,156
FarxigaDapagliflozin Propanediol49$46,325
MounjaroTirzepatide20$21,107
XareltoRivaroxaban30$20,324
Spiriva HandihalerTiotropium Bromide30$17,636
MyrbetriqMirabegron22$17,321
RybelsusSemaglutide12$16,527
TradjentaLinagliptin16$14,753
Breo ElliptaFluticasone/Vilanterol31$14,421
Trelegy ElliptaFluticasone/Umeclidin/Vilanter11$11,438
JanuviaSitagliptin Phosphate11$10,460
Tresiba Flextouch U-200Insulin Degludec14$10,367

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity, Mounjaro$14$160,238145 claims
GSKBreo Ellipta, Trelegy Ellipta, Anoro Ellipta, Arnuity Ellipta$12$37,95075 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 4,428 internal medicine providers in Ohio.

Other internal medicine in Akron

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →